EGFR and non-small cell lung carcinoma: EGFR-TKIs, including the first, second, and third-generation drugs, significantly prolonged progression-free survival (PFS) and overall survival (OS) for advanced NSCLC patients with sensitive EGFR mutations as first-line treatment (Zhou et al., 2011; Maemondo et al., 2010; Fukuoka et al., 2011; Wu et al., 2014; Yang et al., 2015; Wu et al., 2017; Mok et al., 2017).